Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to $19.3 million.

  • Gossamer Bio's Accumulated Expenses rose 1072.15% to $19.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 1072.15%. This contributed to the annual value of $15.2 million for FY2024, which is 4308.1% down from last year.
  • As of Q3 2025, Gossamer Bio's Accumulated Expenses stood at $19.3 million, which was up 1072.15% from $15.6 million recorded in Q2 2025.
  • In the past 5 years, Gossamer Bio's Accumulated Expenses ranged from a high of $31.5 million in Q3 2022 and a low of $14.3 million during Q2 2023
  • Its 4-year average for Accumulated Expenses is $18.8 million, with a median of $17.0 million in 2022.
  • Over the last 5 years, Gossamer Bio's Accumulated Expenses had its largest YoY gain of 2994.35% in 2023, and its largest YoY loss of 4563.48% in 2023.
  • Over the past 4 years, Gossamer Bio's Accumulated Expenses (Quarter) stood at $20.5 million in 2022, then increased by 29.94% to $26.7 million in 2023, then crashed by 43.08% to $15.2 million in 2024, then increased by 27.03% to $19.3 million in 2025.
  • Its Accumulated Expenses was $19.3 million in Q3 2025, compared to $15.6 million in Q2 2025 and $14.8 million in Q1 2025.